ONCOVIN 1mg powder for injection with diluent

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

vincristine sulfate, Quantity: 1 mg

Available from:

Aspen Pharmacare Australia Pty Ltd

Pharmaceutical form:

Injection, powder for

Composition:

Excipient Ingredients: lactose monohydrate

Administration route:

Intravenous

Units in package:

1 vial of powder - 1mg, vial of diluent - 10mL

Prescription type:

(S4) Prescription Only Medicine, Not scheduled. Not considered by committee

Therapeutic indications:

Oncovin is indicated in acute leukaemia. It has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non-Hodgkin's malignant lymphomas(lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types), rhabdomyosarcoma, neuroblastoma, Wilms' tumour, osteogenic sarcoma, mycosis fungoides, Ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung, and gynaecologic tumours of childhood. Patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment may respond to Oncovin. Current practices of cancer chemotherapy involve the simultaneous use of several agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. It is rarely possible to achieve equally good results with single-agent treatment. Thus Oncovin is often chosen as part of polychemotherapy becau

Product summary:

Visual Identification: A white lyophilised powder; Container Type: Multiple containers; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Authorization status:

Registered

Authorization date:

1991-09-05